On March 8, 2024, the FDA approved Wegovy for cardiovascular risk reduction (for reducing the risk of heart attack, stroke, and cardiovascular death) in adult patients with cardiovascular diseases and obesity or overweight in combination with dietary modifications and increased physical activity
Listen to Your Body: Always consult with your healthcare provider before starting any new exercise program
The three-month milestone Clinical data from the SURMOUNT-1 trial reveals a critical finding about the twelve-week mark
By comparison, approximately 1 in 4 participants (27.3%) on semaglutide reached the same target
If you have plateaued on current medications, have fatty liver disease, or simply want to understand what is coming next, retatrutide is the most promising drug in the pipeline
(FYI, the $199/month for the first two months is valid for the 0.25 mg and 0.5 mg doses of Wegovy and is only available until March 31, 2026.) If you pay cash for your prescriptions, the Wegovy Savings Card can bring the cost down to $650 per month, which is on par with the savings offered by the Zepbound Savings Card (for people with commercial drug insurance, but without coverage for Zepbound)
